Chugai’s Value Creation

Our Approach to Value Creation

**Mission Statement**
— Innovation all for the patients —

**Mission**
Dedicate ourselves to adding value by creating and delivering innovative products and services for the medical community and human health around the world

**Core Values**
Patient Centric/Pioneering Spirit/Integrity

**Envisioned Future**
Become a top innovator for advanced and sustainable patient-centric healthcare, powered by our unique strengths in science and technology and the alliance with Roche

**Creation of shared value by Chugai and Society**

Realize advanced and sustainable patient-centric healthcare

**Focus on innovation**
Creation of innovative drugs and services

**Strategic alliance with Roche**

**Chugai’s unique science and technologies**

**Two Revenue Bases**
Strategic Alliance with Roche

**Products In-Licensed from Roche**
- Exclusive domestic sales of breakthrough therapies
- Stable revenue base (Efficient product launches through collaboration with Roche)

**Products from Chugai Research**
- Able to specialize in highly innovative drug discovery
- Revenue base that drives growth (Out-licensing to Roche and global market development)

**Chugai business model adopted**
Chugai has adopted creating shared value with stakeholders as its basic policy.

The goal of this shared value is to bring about the realization of advanced and sustainable patient-centric healthcare. This goal is set forth in our Envisioned Future. While sharing value with our various stakeholders, we will also increase our corporate value by contributing to patients and to the creation of a framework for the next generation of healthcare. That is our approach for value creation.

In the emerging healthcare landscape, rapid advances in life science and digital technology will drive dramatic changes in social structures. Likewise, the healthcare issues that require solutions are expected to become more sophisticated, diverse and complex. Measures to curb drug costs will be tightened further due to financial strains on healthcare systems caused by the growth and aging of populations worldwide, and only solutions that offer true value will be pursued. This situation will make it increasingly difficult for pharmaceutical companies to maintain a sound earnings structure. Rather than being content with its growth thus far, Chugai is shifting to a business structure for concentrating its resources on value creation while making the resolution of social issues the linchpin of its operations.

The key to creating shared value is to focus on innovation. We will continuously generate innovation by fully leveraging our unique business model, which is based on the strategic alliance with Roche and our unique strength in science and technology.

In working to create shared value, Chugai recently specified 25 material issues in eight categories that should be given priority. They were identified through a multifaceted analysis of material issues that incorporated objective views from outside experts. We also set in-house performance indicators to measure our progress in addressing each issue. These material issues may be adjusted in response to changes in the external environment or the evolution of Chugai’s business activities, and we plan to update them periodically.

### 25 Material Issues in 8 Categories

<table>
<thead>
<tr>
<th>Categories</th>
<th>Material Issues</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sustainable healthcare</td>
<td>• Creation of innovative drugs and services&lt;br&gt;• Provision of solutions for patients&lt;br&gt;• Fair marketing&lt;br&gt;• Fair pricing&lt;br&gt;• Adverse event management&lt;br&gt;• Quality assurance and stable supply of products</td>
</tr>
<tr>
<td>Corporate governance</td>
<td>• Corporate governance&lt;br&gt;• Risk management&lt;br&gt;• Disclosure and engagement&lt;br&gt;• Fair transactions</td>
</tr>
<tr>
<td>Ethics and compliance</td>
<td>• Compliance&lt;br&gt;• Code of conduct&lt;br&gt;• Fair transactions</td>
</tr>
<tr>
<td>Supply chain management</td>
<td>• Supply chain management</td>
</tr>
<tr>
<td>Human resources</td>
<td>• Employee job satisfaction&lt;br&gt;• Development of employee potential&lt;br&gt;• Diversity and inclusion&lt;br&gt;• Improvement of occupational health and safety</td>
</tr>
<tr>
<td>Human rights</td>
<td>• Human rights&lt;br&gt;• Safety of clinical trial subjects</td>
</tr>
<tr>
<td>Social contribution</td>
<td>• Social contribution activities&lt;br&gt;• Improvement of access to healthcare</td>
</tr>
<tr>
<td>Global environment</td>
<td>• Climate change countermeasures&lt;br&gt;• Use of renewable/recycled resources&lt;br&gt;• Protection of biodiversity&lt;br&gt;• Environmental management system</td>
</tr>
</tbody>
</table>
Value Shared with Stakeholders

In the context of patient-centric healthcare, we believe that Chugai should contribute to the actual structures and systems needed for realizing advanced, sustainable healthcare, while sharing value with its various stakeholder groups.

For patients, in addition to ensuring high drug efficacy and safety, we must enable them to receive care that matches their values and allows them to maintain their quality of life – in other words, to enable each individual patient to obtain true value. We also need to reduce the various burdens borne by patients' families in connection with treatment and caregiving. For healthcare providers, value includes enabling proper disease control and expanding treatment options. As for insurers and regulators that build the medical insurance and authorization systems, they need to achieve appropriate levels of spending and sustainable healthcare financing so that patients and society can enjoy true value.

For government, enhancing regional healthcare in accordance with the delivery systems in each community where patients live is important. For countries, in addition to improving healthcare finances, development of healthcare as a growth industry is sure to have significant value. For the universities and research companies and institutions that collaborate with Chugai, as well as its partner companies, suppliers, pharmaceutical wholesalers and others, significant value will result from jointly promoting innovation and increasing added value toward the establishment of a framework for the next generation of healthcare. This will lead to sustainable growth for all, and shareholders who invest in the healthcare industry will also be able to share in the benefits of that added value.

Moreover, employees whose work is directly tied to the issue that society expects us to address – realization of advanced and sustainable patient-centric healthcare – will gain job satisfaction, a sense of fulfillment and opportunities to enhance their own abilities.

Chugai believes that sharing value with these various stakeholders beyond mere cooperation is the shortest path to realizing advanced, sustainable healthcare.

The chart to the right shows the material issues that we have identified as having particular importance in our creation of shared value with the stakeholders above.

Relationship between Stakeholders and Material Issues

- **Patients and families of patients**
  - Creation of innovative drugs and services
  - Provision of solutions for patients
  - Adverse event management
  - Quality assurance and stable supply of products
  - Safety of clinical trial subjects
  - Improvement of access to healthcare

- **Healthcare providers and medical institutions**
  - Creation of innovative drugs and services
  - Provision of solutions for patients
  - Fair marketing
  - Adverse event management
  - Quality assurance and stable supply of products

- **Universities and research companies/ institutions**
  - Co-creation of innovation

- **Suppliers and wholesalers, etc.**
  - Economic stability and development

- **Payers and regulators**
  - Sustainable healthcare financing
  - Appropriate spending levels
Chugai has continuously created innovative drugs and delivered them to patients around the world. As creation and development of new drugs becomes increasingly challenging, we intend to create value and deliver it more broadly.

Our value creation has two aspects. One is disease control. We believe that with scientific excellence and the potential of medicines, it is possible to realize medical care in which healthcare providers can control diseases and minimize the suffering of patients, even if they cannot eliminate the disease entirely. This will require the creation of pharmaceuticals that offer both greater efficacy and a high level of safety, and giving healthcare providers the tools to accurately grasp medical conditions.

The other aspect is going beyond treatment with existing pharmaceuticals to provide solutions that offer true value to patients. We believe that the next generation of healthcare will involve delivering overall value to patients by providing treatments that fit their situation and values, and which consider factors such as quality of life after administration of drugs and the psychological, physical and financial burdens. The key here will be proof of value. If we can scientifically measure and assess value for patients, and provide solutions that enhance that value, we can make a significant contribution to improving patients’ lives.

Will Bring true value to patients
• Work toward treatment and disease control
• Contribute to the next generation of healthcare that delivers overall value to patients
Expanding Our Field of View from the Pill to around and beyond the Pill

In the next generation of healthcare that Chugai envisions, value creation entails providing solutions beyond the scope of products, and encompasses not just treatment, but the entire process from prevention and diagnosis to post-treatment.

Solutions to increase the value of drug therapy (“around the pill”) include diagnosis and post-treatment. Even now, diagnosis and treatment are seen as part of an integrated process in personalized healthcare, but with advances in genomic profiling and digital technology, preventive medicine will also play an important role. Furthermore, “beyond the pill” services may include providing solutions using different devices, and even information itself.

Enhancing Overall Value for a Broad Range of Stakeholders

When considering cost effectiveness in terms of healthcare financing, it is necessary to take into account not just the price of the medicine itself, but also the therapeutic effect and impact on the patient’s lifestyle. The cost of a drug varies depending on the dosing frequency and dosing period, and other costs arise from managing adverse events after administration, traveling to and from the hospital, and so on. For instance, some drugs may cost less than others but require significant spending on adverse event management or limit the patient’s ability to work after treatment commences. In such cases, a more expensive drug often provides better overall value because the post-treatment financial burden is smaller. Going forward, it will be important to measure and prove the overall value of a drug, including patients’ ability to maintain employment and a normal lifestyle as well as quality of life.
What We Must Do

Fulfill our obligations as a top pharmaceutical company
• Build a sustainable healthcare framework
• Tirelessly pursue quality in every function

The problem of financing healthcare systems is becoming increasingly serious in many countries. Given the ongoing growth of populations and a rising proportion of seniors, who have relatively greater need for healthcare, providing healthcare sustainably is a critical issue going forward. Moreover, drug discovery is becoming more difficult, and the cost of creating new drugs is enormous. To ensure sustainable healthcare given limited resources, investment will be focused only on solutions that are truly valuable for patients. A framework for such healthcare must be built.

At the same time, on a global scale and from the perspective of social systems as a whole, companies are expected to contribute more broadly and at a more sophisticated level, both in terms of the issues they address and the roles they play. The SDGs adopted by the U.N. are an example of one such international initiative. Chugai supports the aims and philosophy of the SDGs in their entirety, and is working proactively toward their realization.

As a company that has established a solid presence in the industry through its growth and development, Chugai recognizes that it has an obligation to take greater initiative in resolving social issues. While playing a part in realizing sustainable healthcare, we will continue to raise the quality of our activities across all functions by pursuing innovation from the standpoint of increasing shared value with stakeholders. In this way, we will fulfill the role expected of us by society at a higher level.
The Accelerating Increase in Time Requirements and Cost of New Drug Creations

In the drug approval process in various countries, judgment of the novelty of new drugs is becoming increasingly strict. Moreover, while advances in areas such as genomic research and data analysis will contribute substantially to new drug development, the costs associated with these technological breakthroughs are soaring, and global development competition is fierce. According to one study, successfully developing and launching a new drug requires investment of as much as U.S.$2.5 billion, including the cost of projects that quietly fail. Pharmaceutical companies cannot deliver value to patients and grow without the financial strength to shoulder this cost.

Stepping Up Activities Based on SDGs to Create Shared Value

In defining material issues, Chugai verified each issue against the SDGs, and also examined such matters as what role Chugai should play and which goals should be given lower priority considering Chugai’s business. The development goal we are focusing on the most is “3. Good health and well-being.” However, there are also a number of other issues we should work on in partnership with stakeholders. Currently, our main efforts include those listed below. Going forward, we intend to define these development goals in more detail and concentrate on high-priority and high-profile initiatives.

- We support and promote innovation in the field of healthcare by investing aggressively in research and development and by building open innovation networks through collaborative research with academia.
- We adopt a patient-centric approach to creating innovative drugs and providing solutions to cure and manage diseases. Through joint research and other initiatives, we are also working on treatments for neglected tropical diseases, including development of a new therapeutic antibody targeting the dengue virus.
- In addition to recruiting talented and diverse people to support innovation, we provide rewarding environments where employees are able to develop their skills. We strive to optimize work environments and provide systems and conditions that promote job satisfaction and a sense of security among employees. We also expect our suppliers to consider EHS* issues in their business activities.
- In the healthcare industry, we are working to ensure a stable supply and quality at a high level, including the accuracy of product quality and information. We are also promoting the reuse and sustainability of natural resources through efforts including environmental management and targeting water use throughout the value chain.
- To help solve social issues, we are working in collaboration with research organizations, governments, non-governmental organizations and other specialized bodies. We also disclose information to our stakeholders and promote appropriate understanding of our corporate activities through dialogue.

* Environment, health and safety
Can

What We Can Do

Focus on science-based innovation
• Further innovate our unique strengths and technologies
• Take full advantage of cooperation with Roche

We have determined that the key to Chugai’s creation of shared value is to concentrate on innovation. Innovation is an important theme at any company, but we are proud that Chugai has maintained a commitment to science-based innovation ever since it was founded. Innovation is essential to creating breakthrough medicines, but drug discovery is not the only area where we innovate. We have been focusing our efforts on innovation with a scientific approach in all aspects of our business, including development, production, marketing, medical affairs, safety and quality assurance. One example is our use of precise area marketing based on a diverse range of information including real-world data. This approach helps us understand the characteristics of regional healthcare delivery systems and promote cooperation among healthcare providers. Innovating in various fields has allowed Chugai to establish its unique strengths, which are the source of its growth and development. By refining and reinforcing these strengths, we aim to bring about the realization of advanced and sustainable patient-centric healthcare.

Chugai’s concentration on innovation is enabled by its business model, which is based on partnership with Roche, and the efficient, resilient revenue bases that have been built through this model. We intend to make this business structure even stronger so that we can continue to steadily generate innovation.
Use of Chugai’s Unique Strengths and Further Progress

Chugai has unique strengths that give it a competitive advantage and have a considerable impact on the value it provides for patients. The diagram to the left shows how Chugai has redefined those strengths based on the direction of its value creation strategy, changes in the operating environment and other factors. Our business model, which combines scientific excellence with the strategic alliance with Roche, is the source of our value creation. Continuously providing innovative drugs that lead to further advancement of personalized healthcare, and providing healthcare services that maximize their value – these value creation activities are Chugai’s core strengths. We will continue to evolve these strengths by putting our strategies into action.

Optimal Use of Two Revenue Bases Allows Us to Concentrate on Innovation

Under the strategic alliance with Roche, Chugai efficiently in-licenses Roche’s innovative products and markets them on an exclusive basis in Japan. This stable revenue base allows us to concentrate investment on highly innovative proprietary technologies and drug discovery. In addition, out-licensing our in-house products to Roche gives us access to global markets, providing a revenue base that drives growth and generates profits that can be reinvested.

This business model also enables Roche to sell Chugai products – which have been created through highly innovative, specialized in-house research – in global markets. It is truly a win-win relationship. Based on this business model, we will further deepen our cooperation with Roche to drive continued innovation.
Process for Establishing Material Issues

**STEP 1**  
Analysis of mid- to long-term conditions and identification of risks and opportunities  
- Healthcare industry outlook, and forecasts and assumptions of domains and participating companies  
- Identification of future risks and opportunities, and our relevant strengths and weaknesses

**STEP 2**  
Discussion of management policies (Executive Committee)  
- Decisions on management policies and business plan formulation process  
- Discussion on Mission Statement to express both Chugai’s growth and the development of society

**STEP 3**  
Interviews of outside experts  
- Advice of Chugai International Council (CIC) on mid- to long-term environmental changes and risks, strategic direction, and contributions Chugai can make  
- Advice from outside consultants on Chugai’s sustainability activities  
- Extraction of material issue categories based on expectations and requirements of society in accordance with the SDGs, GRI, SASB, etc.  
- Conducted gap analysis of current measures in terms of DJSI, MSCI and FTSE survey items

**STEP 4**  
Gap analysis (requests from outside stakeholders, comparison with other companies)

**STEP 5**  
Analysis of social issues we want to solve (value) and material issues  
- Drew up plan for solutions to social issues of stakeholders (value) and plan for material issues  
- Scope of outcome: “Move toward realization of advanced and sustainable patient-centric healthcare”

**STEP 6**  
Consultation with internal divisions  
- Review of plan for solutions to social issues (value) and plan for material issues, and consultations on wishes and views of divisions and supervising officers (Global Health Policy, Corporate Social Responsibility, Human Resources Management)

**STEP 7**  
Specification of material issues (Outside directors, Executive Committee, Board of Directors)  
- Based on the preceding steps, specified material issues on two axes: “stakeholder interest” and “Chugai’s impact on the economy, society and the environment”  
- Finalization after review by the Executive Committee, and approval by the Board of Directors

In establishing material issues, we analyzed the future market environment, referred to the SDGs, GRI, SASB and other frameworks, and comprehensively identified the issues that society expects Chugai to address. We also scrutinized items for which Chugai is not sufficiently meeting expectations. We conducted an objective analysis that incorporated outside views, and narrowed the list of issues to those for realizing Chugai’s Envisioned Future. Based on that process, we specified 25 material issues in eight categories. (See table on page 17.)
Process for Establishing Material Issues

I think that Chugai’s process for establishing material issues was accurate because in the interest of thoroughness it incorporated gap analyses against an array of indices and objective third-party opinions. Above all, however, my evaluation of the process is positive because decisions are based on historical review and analysis of the medium-to-long-term environment, beginning with the Mission Statement renewal, and took into account consultations with each division and discussions among Chugai’s committees. As a result, the idea of sustainability has been embedded in the new mid-term business plan. As a member of the CSR Advisory Committee, I had the opportunity to offer opinions during the process. I believe that the interrelationships among issues have since been further clarified and made easier to understand.

I am confident in the effectiveness of Chugai’s material issues because in determining them Chugai has eschewed standard formulae and had the will to define issues, risks and opportunities in its own terms.

In the future, Chugai will of course have to take on issues based on its strategies, but dialogue with stakeholders remains important. By using annual reports based upon material issues as a common language in internal and external communications, these issues will become known throughout the Group. I have high expectations that Chugai will be able to craft its own unique approach to sustainability as a result.

Kuniko Muramatsu
Member, Chugai Sustainability Advisory Committee*
Representative Director, Wellness Systems Institute

* Name changed from CSR Advisory Committee as of April 1, 2019